Company: CERO
Filing Date: 2025-01-21
Form Type: S-1/A
Source: 0001213900-25-004742
Chunk: 252

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-01-21
Form: S-1/A
Chunk 252
---
4 at an             
 exercise price of $177.00 per share and (ii) option to purchase 2,550 shares of Common Stock, which vest in two equal installments      
 subject to the satisfaction of certain performance criteria; on December 2, 2024, the board of directors confirmed that the performance 
 criteria had been met with regards to one installment, resulting in the vesting of 1,275 shares under (ii).                             |

| (2) | This                                                                                                                                
 includes the option to purchase 2,550 shares of Common Stock, which vest in two equal installments subject to the satisfaction of   
 certain performance criteria; on December 2, 2024, the board of directors confirmed that the performance criteria had been met with 
 regards to one installment, resulting in the vesting of 1,275 shares. Mr. Patel received $75,000 in consulting fees pursuant to the 
 agreement between Mr. Patel and the Company.                                                                                        |

| (3) | This                                                                                                                                
 includes the option to purchase 1,125 shares of Common Stock  granted to the non-employee director on March 25, 2024 at an exercise 
 price of $177.00 per share; such award was forfeited following the directors resignation from the board of directors.               |

| (4) | This includes the non-employee director compensation for the director which award was forfeited following the director’s resignation from the board of directors. |

159 PRINCIPAL STOCKHOLDERS The following table sets forth information regarding the beneficial ownership of our common stock as of January 8, 2025, by:

| ● | each person known by us to be the beneficial owner of more than 5% of our outstanding shares of Common Stock; |

| ● | each of our named executive officers and directors that beneficially owns shares of our Common Stock; and |

| ● | all our executive officers and directors as a group. |

Beneficial ownership is determined in accordance with the rules and regulations of the SEC, which generally provide that a person has beneficial ownership of a security if he, she or it possesses sole or shared voting or investment power over that security. Shares of our Common Stock subject to options, warrants or shares of Series A Preferred Stock, Series B Preferred Stock or Series C Preferred Stock that are currently exercisable or convertible or exercisable or convertible within 60 days or shares of Common Stock underlying time-based restricted stock units that vest within 60 days are considered outstanding and beneficially owned by the person